BRAIN Biotech AGHAM:BNN -3.89%65 Current Ratio is 1.44 as of Mar. 2026, which is 42% below its 10-year median of 2.48. GuruFocus rates HAM:BNN with a GF Score™ of 65/100 and a GF Value™ of €2.56 (Fairly Valued). The stock has 2 warning signs investors should review. Among 1,609 Chemicals companies, BRAIN Biotech AG ranks worse than 67.12% on this metric.
The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. BRAIN Biotech AG's current ratio for the quarter that ended in Mar. 2026 was 1.44.
BRAIN Biotech AG has a current ratio of 1.44. It generally indicates good short-term financial strength.
The historical rank and industry rank for BRAIN Biotech AG's Current Ratio or its related term are showing as below:
HAM:BNN'
s Current Ratio Range Over the Past 10 Years
Min: 1.37 Med: 2.48 Max: 6.36
Current: 1.44
During the past 11 years, BRAIN Biotech AG's highest Current Ratio was 6.36. The lowest was 1.37. And the median was 2.48.
HAM:BNN's Current Ratio is ranked worse than 67.12% of 1609
companies
in the Chemicals industry
Industry Median: 1.89
vs HAM:BNN: 1.44
BRAIN Biotech AG (HAM:BNN) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
BRAIN Biotech AG Current Ratio Related Terms
BRAIN Biotech AG Current Ratio Historical Data
* Premium members only.
The historical data trend for BRAIN Biotech AG's Current Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HAM:BNN vs LIN, SHW, ECL: Current Ratio Comparison
For the Specialty Chemicals subindustry, BRAIN Biotech AG's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BRAIN Biotech AG Current Ratio vs Chemicals Industry
For the Chemicals industry and Basic Materials sector, BRAIN Biotech AG's Current Ratio distribution charts can be found below:
* The bar in red indicates where BRAIN Biotech AG's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BRAIN Biotech AG (HAM:BNN) has a Current Ratio of 1.44 as of Mar. 2026. This is 42% below median its historical median of 2.48. Over the past decade, BRAIN Biotech AG's Current Ratio has ranged from 1.37 to 6.36. According to the industry distribution chart, BRAIN Biotech AG ranks #1080 out of 1609 companies in the Chemicals industry, placing it in the top 67.1%.
Is BRAIN Biotech AG's Current Ratio too high?
BRAIN Biotech AG's current Current Ratio of 1.44 is 42% below median its 10-year median of 2.48. Over the past 10 years, this metric has ranged from a low of 1.37 to a high of 6.36. The Chemicals industry median Current Ratio is 1.89. BRAIN Biotech AG's value of 1.44 is 23.8% below this industry median. Based on the distribution chart, BRAIN Biotech AG ranks #1080 out of 1609 companies in the Chemicals industry, which is below the industry midpoint. Overall, BRAIN Biotech AG has a GF Score™ of 65/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does BRAIN Biotech AG's Current Ratio compare to LIN and SHW?
According to the Chemicals industry distribution chart, BRAIN Biotech AG ranks #1080 out of 1609 companies for Current Ratio. This places BRAIN Biotech AG in the lower half of its industry. The industry median Current Ratio is 1.89. BRAIN Biotech AG's value of 1.44 is 23.8% below this benchmark. Historically, BRAIN Biotech AG's own Current Ratio has ranged from 1.37 to 6.36 over the past decade. While the company's 10-year median is 2.48 vs. the industry median of 1.89, BRAIN Biotech AG has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Chemicals company?
The median Current Ratio among Chemicals companies is 1.89, based on 1,609 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. BRAIN Biotech AG's current Current Ratio of 1.44 is 23.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Chemicals industry, the median Current Ratio is 1.89 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BRAIN Biotech AG's current Current Ratio is 1.44, which is 42% below median its own 10-year median of 2.48. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BRAIN Biotech AG stock overvalued right now?
Based on GuruFocus' analysis, BRAIN Biotech AG (HAM:BNN) is currently considered Fairly Valued. The stock's GF Value™ is €2.56, compared to a current price of €2.72 — trading 6.3% above its estimated fair value. The current Current Ratio is 1.44, which is 42% below median its 10-year median of 2.48 and 23.8% below the Chemicals industry median of 1.89. BRAIN Biotech AG's overall GF Score™ is 65/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For BRAIN Biotech AG (HAM:BNN), the current Current Ratio is 1.44 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BRAIN Biotech AG (HAM:BNN) Overvalued in 2026?
Based on GuruFocus' analysis, BRAIN Biotech AG stock appears to be overvalued.
The current stock price of €2.72 is trading 6.3% above its estimated GF Value™ of €2.56.
GuruFocus considers BRAIN Biotech AG to be Fairly Valued.
Key valuation signals for HAM:BNN:
Current Ratio: 1.44 (42% below median its 10-year median of 2.48)
GF Value™: €2.56 vs. price of €2.72 (6.3% above fair value)
Industry Position: 23.8% below the Chemicals median (#1080 of 1609)
No single metric tells the full story. See the HAM:BNN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
BRAIN Biotech AG is an industrial biotechnology specialist focused on enzyme technology, microbial production strains, and bioprocess design to enable bio-based innovations. The Group conducts research, development, and production for client specifications and its own product portfolio, supporting customers in the food and beverage, chemical, and life sciences industries with solutions that enhance productivity, efficiency, and sustainability. Its operations are organized into two segments: BRAIN Biocatalysts, which develops, produces, and distributes specialty enzymes, microorganisms, and ingredients and generates the majority of revenue, and BRAIN BioIncubator, which focuses on development projects. The company operates in Germany and other countries.
65GF Score
Get the complete analysis for HAM:BNN
Current Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HAM:BNN has been successfully added to your 
